Figure 5. Cumulative risk of major adverse cardiovascular outcomes (myocardial infarction, stroke, and mortality), stratified by baseline atherosclerotic cardiovascular diseases (CVDs) and heart failure (HF) (as‐treated analyses adjusted for baseline confounding and informative censoring).

GLP‐1RA indicates glucagon‐like peptide‐1 receptor agonists; and SGLT2i, sodium‐glucose cotransporter‐2 inhibitors.